Mumbai/IBNS, Feb. 24 -- The share prices of Indoco Remedies Ltd. on Tuesday climbed almost 7% after the company received the final Abbreviated New Drug Application (ANDA) from US Food and Drug Administration (USFDA) for Brivaracetam Oral Solution, 10 mg/mL, to market, CNBC TV 18 reported.

Brivaracetam Oral Solution is a generic equivalent to the reference listed drug (RLD), Briviact 10 mg/mL, of UCB, Inc.

Brivaracetam Oral Solution will be manufactured by Indoco Remedies Limited, at their manufacturing facility located at L-14, Verna Industrial Area, Verna, Goa - 403722 in India.

Brivaracetam Oral Solution (10 mg/mL) is a prescription antiepileptic drug (anticonvulsant) used for treatment of partial-onset seizures in patients 1 month o...